We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The U.S. Patent and Trademark Office rejected claims in a key patent covering Genentech’s respiratory treatment drug, Synagis, the company said, noting that it is contemplating challenging the decision.
Watson Pharmaceuticals has agreed to license its bupropion hydrochloride absorption method patent for $35 million as part of a settlement to resolve patent litigation regarding GlaxoSmithKline’s (GSK) Wellbutrin XL.
Days before the start of a hearing challenging India’s drug patent laws, House Oversight and Government Reform Committee Chairman Henry Waxman (D-Calif.) called for an end to the challenge by Novartis, saying that a victory for the company could limit access to low-cost generic drugs.
A federal court has ruled against sanofi-aventis in its patent infringement suit against Amphastar and Teva, paving the way for the FDA to review generic versions of the anticoagulant drug Lovenox.
The FTC will continue to pursue an anticompetitive case against Barr Laboratories following a federal district court ruling rejecting the generic firm’s motion to dismiss the case, agency sources say.
Days before the start of a hearing challenging India’s drug patent laws, House Oversight and Government Reform Committee Chairman Henry Waxman (D-Calif.) called for an end to the challenge by Novartis, saying that a victory for the company could limit access to low-cost generic drugs.
Days before the start of a hearing challenging India’s drug patent laws, House Oversight and Government Reform Committee Chairman Henry Waxman (D-Calif.) called for an end to the challenge by Novartis, saying that a victory for the company could limit access to low-cost generic drugs.
Watson Pharmaceuticals has agreed to license its bupropion hydrochloride absorption method patent for $35 million as part of a settlement to resolve patent litigation regarding GlaxoSmithKline’s (GSK) Wellbutrin XL.
A federal court has ruled against sanofi-aventis in its patent infringement suit against Amphastar and Teva, paving the way for the FDA to review generic versions of the anticoagulant drug Lovenox.